Загрузка...
Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
Alogliptin is a selective dipeptidyl peptidase-4 inhibitor recently marketed for once-daily administration in the treatment of type 2 diabetes mellitus (T2DM). Fixed-dose combinations of alogliptin with both metformin and pioglitazone are also commercially available, providing a measure of convenien...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4090041/ https://ncbi.nlm.nih.gov/pubmed/25050071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S37648 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|